Page 349

House Bill No. 5506

Public Act No. 22-118 349 of 739

information technology officer as set forth in sections 17b-59f and 17b- 59g. (d) Any order or regulation of the entities listed in subdivisions (1) and (2) of subsection (c) of this section that is in force on July 1, 2018, shall continue in force and effect as an order or regulation until amended, repealed or superseded pursuant to law. Sec. 218. (NEW) (Effective from passage) For the purposes of this section and sections 219 to 223, inclusive, of this act: (1) "Drug manufacturer" means the manufacturer of a drug that is: (A) Included in the information and data submitted by a health carrier pursuant to section 38a-479qqq of the general statutes, (B) studied or listed pursuant to subsection (c) or (d) of section 19a-754b of the general statutes, or (C) in a therapeutic class of drugs that the executive director determines, through public or private reports, has had a substantial impact on prescription drug expenditures, net of rebates, as a percentage of total health care expenditures; (2) "Executive director" means the executive director of the Office of Health Strategy; (3) "Health care cost growth benchmark" means the annual benchmark established pursuant to section 219 of this act; (4) "Health care quality benchmark" means an annual benchmark established pursuant to section 219 of this act; (5) "Health care provider" has the same meaning as provided in subdivision (1) of subsection (a) of section 19a-17b of the general statutes; (6) "Net cost of private health insurance" means the difference between premiums earned and benefits incurred, and includes insurers'